Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B-cell-like [ABC], germinal-center B-cell-like [GCB], and unclassified) according to cell of origin that are associated with a differential response to chemotherapy and targeted agents. We sought to extend these findings by identifying genetic subtypes of DLBCL based on shared genomic abnormalities and to uncover therapeutic vulnerabilities based on tumor genetics. METHODS: We studied 574 DLBCL biopsy samples using exome and transcriptome sequencing, array-based DNA copy-number analysis, and targeted amplicon resequencing of 372 genes to identify genes with recurrent aberrations. We developed and implemented an algorithm to discover genetic subtypes based on the co-occurrence of genetic alterations. RESULTS: and CD79B mutations), BN2 (based on BCL6 fusions and NOTCH2 mutations), N1 (based on NOTCH1 mutations), and EZB (based on EZH2 mutations and BCL2 translocations). Genetic aberrations in multiple genes distinguished each genetic subtype from other DLBCLs. These subtypes differed phenotypically, as judged by differences in gene-expression signatures and responses to immunochemotherapy, with favorable survival in the BN2 and EZB subtypes and inferior outcomes in the MCD and N1 subtypes. Analysis of genetic pathways suggested that MCD and BN2 DLBCLs rely on "chronic active" B-cell receptor signaling that is amenable to therapeutic inhibition. CONCLUSIONS: We uncovered genetic subtypes of DLBCL with distinct genotypic, epigenetic, and clinical characteristics, providing a potential nosology for precision-medicine strategies in DLBCL. (Funded by the Intramural Research Program of the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“LBCL is genetically and biologically heterogeneous. This diversity includes both tumor and the corresponding tumor microenvironment (TME), and it affects response to standard immunochemotherapy.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Self-citationRosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Self-citationStromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,808
Self-citationChronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,643
Self-citationOncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.-H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2011) · Nature · doi:10.1038/nature09671 · Cited by 1,512
Self-citationTargeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Lih, C.-J., Williams, P. M., Shaffer, A. L., Gerecitano, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3884 · Cited by 1,113
Self-citationA loss-of-function RNA interference screen for molecular targets in cancer
Ngo, V. N., Davis, R. E., Lamy, L., Yu, X., Zhao, H., Lenz, G., Lam, L. T., Dave, S., Yang, L., Powell, J., et al. (2006) · Nature · doi:10.1038/nature04687 · Cited by 605
Self-citationExploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yang, Y., Shaffer, A. L., Emre, N. C. T., Ceribelli, M., Zhang, M., Wright, G., Xiao, W., Powell, J., Platig, J., Kohlhammer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.024 · Cited by 521
Self-citationInhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Lionakis, M. S., Dunleavy, K., Roschewski, M., Widemann, B. C., Butman, J. A., Schmitz, R., Yang, Y., Cole, D. E., Melani, C., Higham, C. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.012 · Cited by 508
Self-citationChalla-Malladi, M., Lieu, Y. K., Califano, O., Holmes, A. B., Bhagat, G., Murty, V. V., Dominguez-Sola, D., Pasqualucci, L., & Dalla-Favera, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.006 · Cited by 439
Cited by
Items 801–900 of 1,000
2026 Update on the Management of Diffuse Large B‐Cell Lymphoma
Chong, E. A., Tomasulo, E. B., & Barta, S. K. (2026) · American Journal of Hematology · doi:10.1002/ajh.70229 · Cited by 15
The clinicopathological features of parotid lymphoma.
Wang, J., Li, R., Wang, Q., Chen, Y., Gao, T., Han, R., Li, N., & Zhang, K. (2020) · PubMed · Cited by 15
Self-citationZhong, Q., & Shi, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.582567 · Cited by 15
Chen, H., Zhong, Q., Zhou, Y. L., Qin, Y., Yang, J., Liu, P., He, X., Zhou, S., Zhang, C., Gui, L., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09693-z · Cited by 15
Prevalence of IRF4 rearrangement in large B-cell lymphomas of the Waldeyer’s ring in adults
Streich, S., Frauenfeld, L., Otto, F., Mankel, B., Bonzheim, I., Fend, F., & Quintanilla‐Martínez, L. (2023) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-023-03516-7 · Cited by 15
Flümann, R., Hansen, J., Meinel, J., Pfeiffer, P., Goldfarb-Wittkopf, H., Lütz, A., Wirtz, J., Möllmann, M., Zhou, T., Tabatabai, A., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011213 · Cited by 15
Atallah‐Yunes, S. A., Khurana, A., & Maurer, M. J. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2298705 · Cited by 15
Cauwelier, C., de Ridder, I., & Bultynck, G. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2024.119713 · Cited by 15
Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Meriranta, L., Sorri, S., Huse, K., Liu, X., Spasevska, I., Zafar, S., Chowdhury, I. M., Dufva, O., Sahlberg, E., Tandarić, L., et al. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0182 · Cited by 15
Self-citationMYC-rearranged mature B-cell lymphomas in children and young adults are molecularly Burkitt Lymphoma
Mato, S., de Anta, N. C., Colmenero, A., Carità, L., Salmerón‐Villalobos, J., Ramis-Zaldivar, J. E., Nadeu, F., Garcia, N., Wang, L., Verdú‐Amorós, J., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01153-0 · Cited by 15
Self-citationClinical use of circulating tumor DNA analysis in patients with lymphoma
Bisig, B., Lefort, K., Carras, S., & de Leval, L. (2024) · Human Pathology · doi:10.1016/j.humpath.2024.105679 · Cited by 15
Lone, W., Bouska, A. C., Herek, T. A., Amador, C., Song, J. Y., Xu, A. M., Jochum, D. T., Issa, I. I., Weisenburger, D. D., Zhang, X., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27513 · Cited by 15
Self-citationAn updated understanding of follicular lymphoma transformation
Parry, E. M., & Okosun, J. (2025) · Blood · doi:10.1182/blood.2024026016 · Cited by 15
Cassidy, D. P., Chapman, J. R., Lopez, R., White, K., Fan, Y., Casas, C. E., Severson, E. A., & Vega, F. (2019) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqz172 · Cited by 15
D'Angelo, C. R., Hanel, W. G., Chen, Y., Yu, M., Yang, D. T., Guo, L., Karmali, R., Burkart, M., Ciccosanti, C., David, K. A., et al. (2021) · Hematological Oncology · doi:10.1002/hon.2902 · Cited by 15
Fjordén, K., Ekberg, S., Kuric, N., Smedby, K. E. E., Lagerlöf, I., Larsen, T. S., Jørgensen, J. M., Brown, P. D. N., & Jerkeman, M. (2021) · British Journal of Haematology · doi:10.1111/bjh.17792 · Cited by 15
Dlouhy, I., Karube, K., Enjuanes, A., Salaverría, I., Nadeu, F., Ramis-Zaldivar, J. E., Valero, J. G., Rivas‐Delgado, A., Magnano, L., Martin‐García, D., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17858 · Cited by 15
Self-citationIdeal dose intensity of R-CHOP in diffuse large B-cell lymphoma
Miura, K., Takahashi, H., Nakagawa, M., Hamada, T., Uchino, Y., Iizuka, K., Ohtake, S., Iriyama, N., Hatta, Y., & Nakamura, H. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2071262 · Cited by 15
Xu, P., Shen, R., Shi, Z., Cheng, S., Wang, L., Liu, Y., Zhang, L., Huang, R., Ma, X., Wu, X., et al. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.08.006 · Cited by 15
Zhang, Y., LeWitt, T. M., Louissaint, A., Guitart, J., Zhou, X. A., & Choi, J. (2022) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.07.027 · Cited by 15
Roles of G4-DNA and G4-RNA in Class Switch Recombination and Additional Regulations in B-Lymphocytes
Dézé, O., Laffleur, B., & Cogné, M. (2023) · Molecules · doi:10.3390/molecules28031159 · Cited by 15
The biology and treatment of Epstein-Barr virus-positive diffuse large B cell lymphoma, NOS
Li, J. Y., Deng, C., Zhou, X., & Deng, R. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23921 · Cited by 15
The Emerging Role of Minimal Residual Disease Testing in Diffuse Large B-Cell Lymphoma
Hu, R., Winter, A. M., & Hill, B. T. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0792-4 · Cited by 15
Tarantelli, C., Gaudio, E., Hillmann, P., Spriano, F., Sartori, G., Aresu, L., Cascione, L., Rageot, D., Kwee, I., Beaufils, F., et al. (2019) · Cancers · doi:10.3390/cancers11060775 · Cited by 15
Chiappella, A., Crombie, J. L., Guidetti, A., Vitolo, U., Armand, P. A., & Corradini, P. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000284 · Cited by 15
Therapeutic potential of PI3K signaling in distinct entities of B-cell lymphoma
Stelmach, R., Friedrichs, B., Erdmann, T., & Lenz, G. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1676716 · Cited by 15
Luminari, S., Donati, B., Casali, M., Valli, R., Santi, R., Puccini, B., Kovalchuk, S., Ruffini, A., Famà, A., Berti, V., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2356 · Cited by 15
Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma
Crombie, J. L., & Armand, P. A. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.08.009 · Cited by 15
Co-expression Networks Identify DHX15 RNA Helicase as a B Cell Regulatory Factor
Detanico, T., Virgen‐Slane, R., Steen-Fuentes, S., Lin, W., Rhode-Kurnow, A., Chappell, E., Correa, R. G., DiCandido, M. J., Mbow, M. L., Li, J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02903 · Cited by 15
Barış, İ. C., Hacıoğlu, S., Türk, N. Ş., Cetın, G. O., Zencir, S., Bağcı, G., & Caner, V. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02504-6 · Cited by 15
A 6‐lncRNA signature predicts prognosis of diffuse large B‐cell lymphoma
Gao, H., Wu, B., Jin, H., & Yang, W. (2021) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22768 · Cited by 15
Li, B., Huang, Z., Yu, W., Liu, S., Zhang, J., Wang, Q., Wu, L., Kou, F., & Yang, L. (2021) · Neoplasia · doi:10.1016/j.neo.2021.05.006 · Cited by 15
Histone Modifications and Their Targeting in Lymphoid Malignancies
Fernández-Serrano, M., Winkler, R., Santos, J. C., Pannérer, M.-M. L., Buschbeck, M., & Roué, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010253 · Cited by 15
Yang, Y., Chen, R., Gong, Y., Yang, W., Li, K., Fan, W., Gou, S., Gao, P., He, T., & Cai, K. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121607 · Cited by 15
Self-citationLiu, H., Yang, C., Zhao, X., Le, J., Wu, G., Wei, J., Liang, Y., & Qian, W. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s275334 · Cited by 15
Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts
Yi, J. H., Jeong, S. H., Kim, S. J., Yoon, D. H., Kang, H. J., Koh, Y., Kim, J. S., Lee, W.-S., Yang, D., Do, Y. R., et al. (2022) · Cancer Research and Treatment · doi:10.4143/crt.2022.008 · Cited by 14
Yenamandra, A. K., Smith, R. B., Senaratne, T. N., Kang, S.-H. L., Fink, J. M., Corboy, G., Hodge, C. A., Lu, X. Y., Mathew, S., Crocker, S. F., et al. (2022) · Cancer Genetics · doi:10.1016/j.cancergen.2022.07.006 · Cited by 14
Pickard, K., Stephenson, E., Mitchell, A., Jardine, L., & Bacon, C. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1258245 · Cited by 14
Berendsen, M. R., van Bladel, D. A. G., Hesius, E. A. M., Irusquieta, C. B., Rijntjes, J., van Spriel, A. B., van der Spek, E., Pruijt, H., Kroeze, L. I., Hebeda, K. M., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000976 · Cited by 14
Zhu, M., Drill, E. N., Joffe, E., Salles, G. A., Rivas‐Delgado, A., Zelenetz, A. D., Palomba, M. L., Arcila, M. E., & Doǧan, A. (2024) · Haematologica · doi:10.3324/haematol.2023.284565 · Cited by 14
Self-citationArffman, M., Meriranta, L., Autio, M. I., Holte, H., Jørgensen, J. M., Brown, P. D. N., Jyrkkiö, S. M., Jerkeman, M., Drott, K., Fluge, Ø., et al. (2024) · Med · doi:10.1016/j.medj.2024.03.007 · Cited by 14
Yoshifuji, K., Sadato, D., Toya, T., Motomura, Y., Hirama, C., Takase, H., Yamamoto, K., Harada, Y., Mori, T., & Nagao, T. (2024) · Haematologica · doi:10.3324/haematol.2023.284953 · Cited by 14
Santamaria‐Martínez, A., Epiney, J., Srivastava, D., Tavernari, D., Varrone, M., Milowich, D., Letovanec, I., Krueger, T., Durán, R., Ciriello, G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-55098-w · Cited by 14
Zanelli, M., Sanguedolce, F., Zizzo, M., Ricci, S., Bisagni, A., Palicelli, A., Fragliasso, V., Donati, B., Broggi, G., Boutas, I., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313213 · Cited by 14
Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas
Chihara, D., Steiner, R. E., Nair, R. K., Feng, L., Ahmed, S., Strati, P., Malpica, L., Griffith, D., Mathew, S. A., Montinez, W., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024014635 · Cited by 14
Duan, Z., Wang, W., Wang, Y., Wang, R., Hua, W., Shang, C., Gao, R., Shen, H., Li, Y., Wu, J., et al. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70246 · Cited by 14
Self-citationLarge B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment
Pelzl, R. J., Benintende, G., Gsottberger, F., Scholz, J. K., Ruebner, M., Yao, H., Wendland, K., Rejeski, K., Altmann, H., Petkovic, S., et al. (2025) · Blood · doi:10.1182/blood.2024027877 · Cited by 14
Walker, J. S., Wenzl, K., Novak, J. P., Stokes, M. E., Hopper, M. A., Dropik, A. R., Siminski, M. S., Bock, A. M., Sarangi, V., Ortiz, M., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01326-5 · Cited by 14
Aghayan, A. H., Bayani, A., Abbaspour, M., Gharehchahi, F., & Samarkhazan, H. S. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104884 · Cited by 14
Shanmugam, V., Tokcan, N., Chafamo, D., Sullivan, S., Borji, M., Martin, H. K., Newton, G. A., Nadaf, N. M., Hanbury, S., Barrera, I., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67539-1 · Cited by 14
DLBCL subclassification: divide and conquer?
Morin, R. D., & Scott, D. W. (2020) · Blood · doi:10.1182/blood.2020005335 · Cited by 14
Human B Lymphomas Reveal Their Secrets Through Genetic Mouse Models
Mossadegh‐Keller, N., Brisou, G., Beyou, A., Nadel, B., & Roulland, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.683597 · Cited by 14
Self-citationThe developmental origins of Notch-driven intrahepatic bile duct disorders
Lyons, A. M., & Boulter, L. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.048413 · Cited by 14
Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment
Danilov, A. V., Magagnoli, M., & Matasar, M. J. (2022) · The Oncologist · doi:10.1093/oncolo/oyab004 · Cited by 14
Genta, S., Ghilardi, G., Cascione, L., Juškevičius, D., Tzankov, A., Schär, S., Milan, L., Pirosa, M. C., Esposito, F., Ruberto, T., et al. (2022) · Cancers · doi:10.3390/cancers14041018 · Cited by 14
Molecular Diagnostic Review of Diffuse Large B-Cell Lymphoma and Its Tumor Microenvironment
Ta, R. M., Yang, D. T., Hirt, C., Drago, T. J., & Flavin, R. (2022) · Diagnostics · doi:10.3390/diagnostics12051087 · Cited by 14
Prognostic factors in primary central nervous system lymphoma
Morales-Martínez, A., Nichelli, L., Hernández-Verdín, I., Houillier, C., Alentorn, A., & Hoang‐Xuan, K. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000896 · Cited by 14
Molecular Pathogenesis of Follicular Lymphoma: From Genetics to Clinical Practice
López, C., Mozas, P., López‐Guillermo, A., & Beà, S. (2022) · Hemato · doi:10.3390/hemato3040041 · Cited by 14
The RNA helicase DDX3 and its role in c-MYC driven germinal center-derived B-cell lymphoma
Lacroix, M., Beauchemin, H., Khandanpour, C., & Möröy, T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1148936 · Cited by 14
The germinal center in the pathogenesis of B cell lymphomas
Pasqualucci, L. (2023) · Hematological Oncology · doi:10.1002/hon.3141 · Cited by 14
Milano, A. F. (2023) · Journal of Insurance Medicine · doi:10.17849/insm-50-1-1-35.1 · Cited by 14
Zhang, Y., Geng, H., Zeng, L., Li, J., Yang, Q., Jia, S., Zong, X., Cai, W., Liu, S., Lu, Y., et al. (2023) · Hematological Oncology · doi:10.1002/hon.3227 · Cited by 14
Ivanova, V., Davies, J., Menter, T., Wild, D., Mueller, A., Krasniqi, F., Stenner, F., Papachristofilou, A., Dirnhofer, S., & Tzankov, A. (2023) · Histopathology · doi:10.1111/his.15096 · Cited by 14
Eriksen, P. R. G., de Groot, F. A., Clasen‐Linde, E., Brown, P. D. N., de Groen, R. A. L., Melchior, L., Maier, A. D., Minderman, M., Vermaat, J. S. P., von Buchwald, C., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011517 · Cited by 14
Karube, K., Satou, A., & Kato, S. X. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03781-5 · Cited by 14
Hori, Y., Yamamoto, H., Nozaki, Y., Torisu, T., Fujiwara, M., Taguchi, K., Nishiyama, K., Nakamura, S., Kitazono, T., & Oda, Y. (2019) · Human Pathology · doi:10.1016/j.humpath.2019.09.003 · Cited by 14
Sawalha, Y., & Maddocks, K. J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s219449 · Cited by 14
Kuang, Z., Li, X., Liu, R., Chen, S., & Tu, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.648856 · Cited by 14
Jiang, X., Zhang, Y., Wang, W., Sheng, D., Zhou, X., & Li, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.608238 · Cited by 14
Cai, J., Tian, X., Ma, S., Zhong, L., Li, W., Wang, L., Guo, L., Li, Z., Wu, Y., Zhong, G., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01434-6 · Cited by 14
IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma
Elfrink, S., ter Beest, M., Janssen, L., Baltissen, M. P. A., Jansen, P. W. T. C., Kenyon, A. N., Steen, R. M., de Windt, D., Hagemann, P. M., Hess, C. J., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021004366 · Cited by 14
PARK2 Regulates eIF4B-Driven Lymphomagenesis
Kapadia, B. B., Roychowdhury, A., Kayastha, F., Nanaji, N., & Gartenhaus, R. B. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0729 · Cited by 14
CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives
Sheikh, S., Migliorini, D., & Lang, N. (2022) · Biomedicines · doi:10.3390/biomedicines10081960 · Cited by 14
The clinicopathological and genetic features of ovarian diffuse large B-cell lymphoma
Xu, H., Duan, N., Wang, Y., Sun, N., Ge, S., Li, H., Jing, X., Ke, L., Zhang, X., Liu, L., et al. (2019) · Pathology · doi:10.1016/j.pathol.2019.09.014 · Cited by 14
Tateishi, K., Miyake, Y., Nakamura, T., & Yamamoto, T. (2021) · Brain Tumor Pathology · doi:10.1007/s10014-021-00408-z · Cited by 14
The GA4GH Phenopacket schema: A computable representation of clinical data for precision medicinePreprint
Jacobsen, J. O. B., Baudis, M., Baynam, G. S., Beckmann, J. S., Beltrán, S., Callahan, T. J., Chute, C. G., Courtot, M., Daniš, D., Elemento, O., et al. (2021) · medRxiv · doi:10.1101/2021.11.27.21266944 · Cited by 14
Primary Testicular Lymphoma: Single Center Experience
Shah, S. S., Sreenivasan, S., Kancharla, P., Khan, C., & Samhouri, Y. (2023) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10192 · Cited by 13
Reiss, D. J., Nakayama, Y., Weng, A. P., Stokes, M. E., Sehn, L. H., Steidl, C., Scott, D. W., Huang, C. C., & Gandhi, A. K. (2024) · Leukemia · doi:10.1038/s41375-024-02239-1 · Cited by 13
Autio, M. I., Brück, O. E., Pollari, M., Karjalainen‐Lindsberg, M., Beiske, K., Jørgensen, J. M., Holte, H., Pellinen, T. S., Leivonen, S., & Leppä, S. (2024) · Haematologica · doi:10.3324/haematol.2024.286267 · Cited by 13
Coughlin, C. A., Chahar, D., Lekakis, M., Youssfi, A. A., Li, L., Roberts, E., Gallego, N. C., Volmar, C., Landgren, O., Brothers, S. P., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01214-y · Cited by 13
Yang, H., Zhang, W., Ravanmehr, V., Cui, G., Bowman, K., Chen, R., Henderson, J. M., Lockman, S. R., Rojas, E., Wilson, A., et al. (2025) · Blood · doi:10.1182/blood.2024026664 · Cited by 13
Wang, X., He, J., Ding, G., Tang, Y., & Wang, Q. (2026) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s572089 · Cited by 13
Deciphering the genetic landscape of pulmonary lymphomas
Vela, V., Juškevičius, D., Prince, S. S., Cathomas, G., Dertinger, S., Diebold, J., Bubendorf, L., Horcic, M., Singer, G., Zettl, A., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-00660-2 · Cited by 13
Tsai, C.-C., Su, Y.-C., Bamodu, O. A., Chen, B., Tsai, W., Cheng, W.-H., Lee, C.-H., Hsieh, S.-M., Liu, M.-L., Fang, C.-L., et al. (2021) · Cancers · doi:10.3390/cancers13071620 · Cited by 13
Calimeri, T., Marcucci, F., & Corti, A. (2021) · Annals of Lymphoma · doi:10.21037/aol-20-54 · Cited by 13
de Groot, F. A., de Groen, R. A. L., van den Berg, A., Jansen, P. M., Lam, K. H., Mutsaers, P., van Noesel, C. J. M., Chamuleau, M. E. D., Stevens, W. B. C., Plaça, J. R., et al. (2022) · Cancers · doi:10.3390/cancers14081857 · Cited by 13
Ning, N., Zhang, S., Wu, Q., Li, X., Kuang, D., Duan, Y., Xia, M., Liu, H., Weng, J., Ba, H., et al. (2022) · Theranostics · doi:10.7150/thno.72786 · Cited by 13
Self-citationMa, D., Ma, Y., Ma, Y., Liu, J. S., Gu, Y., Liu, N., Xiang, C., Liu, H., & Sang, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.941347 · Cited by 13
Hernández-Verdín, I., Morales-Martínez, A., Hoang‐Xuan, K., & Alentorn, A. (2022) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001115 · Cited by 13
Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma
Ebid, O. A. E. H., Arab, L. R. E. E., Saad, A. S., Din, M. E. E., Mostafa, N., & Swellam, M. M. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05420-1 · Cited by 13
Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS
de Jonge, A. V., Duetz, C., Bruins, W. S. C., Korst, C. L. B. M., Rentenaar, R., Cosovic, M., Eken, M., Twickler, I., Nijland, M., van der Poel, M., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011687 · Cited by 13
Gergely, L., Udvardy, M., & Illés, Á. (2024) · Biomedicines · doi:10.3390/biomedicines12030648 · Cited by 13
Baron, M., Labrèche, K., Veyri, M., Désiré, N., Bouzidi, A., Seck-Thiam, F., Charlotte, F., Rousseau, A., Morin, V., Nakid-Cordero, C., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.284332 · Cited by 13
Arribas, A. J., Napoli, S., Gaudio, E., Herbaux, C., Cannas, E., Tarantelli, C., Pittau, R. B., Cascione, L., Munz, N., Aresu, L., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012291 · Cited by 13
El‐Galaly, T. C., Cheah, C. Y., & Villa, D. R. (2019) · British Journal of Haematology · doi:10.1111/bjh.15965 · Cited by 13
Zhao, H., Kan, Y., Wang, X., Chen, L., Ge, P., & Qian, Z. (2019) · Bioscience Reports · doi:10.1042/bsr20191162 · Cited by 13
Self-citationPerspectives on chemotherapy for the management of double-hit lymphoma
Al-Juhaishi, T. M. S., McKay, J., Sindel, A. D., & Yazbeck, V. Y. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1727445 · Cited by 13
Crotty, R. K., Hu, K., Stevenson, K. E., Pontius, M. Y., Sohani, A. R., Ryan, R. J. H., Rueckert, E. H., Brauer, H. A., Hudson, B. M., Berlin, A. M., et al. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa185 · Cited by 13
Molecular classification of aggressive lymphomas—past, present, future
Wienand, K., & Chapuy, B. (2021) · Hematological Oncology · doi:10.1002/hon.2847 · Cited by 13
Chen, H., Qin, Y., Yang, J., Liu, P., He, X., Zhou, S., Zhang, C., Gui, L., Yang, S., & Shi, Y. (2021) · Leukemia Research · doi:10.1016/j.leukres.2021.106715 · Cited by 13
Metadata
- Authors
- Schmitz, R., Wright, G. W., Huang, D. W., Johnson, C. A., Phelan, J. D., Wang, J. Q., Roulland, S., Kasbekar, M., Young, R. M., Shaffer, A. L., Hodson, D. J., Xiao, W., Yu, X., Yang, Y., Zhao, H., Xu, W., Liu, X., Zhou, B., Du, W., Chan, W. C., Jaffe, E. S., Gascoyne, R. D., Connors, J. M., Campo, E., Lopez-Guillermo, A., Rosenwald, A., Ott, G., Delabie, J., Rimsza, L. M., Tay Kuang Wei, K., Zelenetz, A. D., Leonard, J. P., Bartlett, N. L., Tran, B., Shetty, J., Zhao, Y., Soppet, D. R., Pittaluga, S., Wilson, W. H., & Staudt, L. M.
- Affiliations
- National Cancer Institute (US)
- National Institutes of Health (US)
- City Of Hope National Medical Center (US)
- BC Cancer Agency (CA)
- From the Lymphoid Malignancies Branch (R.S., D.W.H., J.D.P., J.Q.W., S.R., M.K., R.M.Y., A.L.S., D.J.H., W. Xiao, X.Y., Y.Y., H.Z., W. Xu, W.H.W., L.M.S.), the Biometric Research Program, Division of Cancer Diagnosis and Treatment (G.W.W.), and the Laboratory of Pathology, Center for Cancer Research (E.S.J., S.P.), National Cancer Institute, and the Office of Intramural Research, Center for Information Technology (C.A.J., X.L., B.Z., W.D.), National Institutes of Health, Bethesda, and the Cancer...
- University of Würzburg (DE)
- Robert Bosch Hospital (DE)
- University Health Network (CA)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- Alliance for Clinical Trials in Oncology (US)
- Washington University in St. Louis (US)
- Frederick National Laboratory for Cancer Research (US)
- ORCID
- Schmitz, Roland
- Wright, George W.
- Huang, Da Wei
- Phelan, James D.
- Wang, James Q.
- Roulland, Sandrine
- Kasbekar, Monica
- Young, Ryan M.
- Shaffer, Arthur L.
- Hodson, Daniel J.
- Xiao, Wenming
- Yu, Xin
- Yang, Yandan
- Zhao, Hong
- Zhou, Bin
- Chan, Wing C.
- Jaffe, Elaine S.
- Gascoyne, Randy D.
- Connors, Joseph M.
- Rosenwald, Andreas
- Ott, German
- Delabie, Jan
- Rimsza, Lisa M.
- Zelenetz, Andrew D.
- Leonard, John P.
- Bartlett, Nancy L.
- Tran, Bao
- Shetty, Jyoti
- Zhao, Yongmei
- Pittaluga, Stefania
- Wilson, Wyndham H.
- Staudt, Louis M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-04-12
- Volume
- 378
- Issue
- 15
- Pages
- 1396-1407
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6010183
- OpenAlex
- W2797584152
- Cited by
- 2,241
- References
- 30
- Citations by year
- 2026: 193 · 2025: 271 · 2024: 320 · 2023: 339 · 2022: 317 · 2021: 302 · 2020: 250 · 2019: 191 · 2018: 53
- FWCI
- 153.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- National Cancer Institute Strategic Partnering to Evaluate Cancer Signatures (SPECS II) grant (5U01CA157581-05)
- Intramural Research Program of the NIH, National Cancer Institute
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- diffuse large B-cell lymphoma, genetic subtypes, B cell receptor signaling, NOTCH1 mutation, NOTCH2 mutation, EZH2 mutation, BCL2 translocation, CD79B mutation, germinal center B-cell-like lymphoma, therapeutic vulnerabilities, precision medicine, survival outcomes
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Biopsy, Genotype, Humans, Mutation, Prognosis, Lymphoma, Large B-Cell, Diffuse, Sequence Analysis, DNA, Genetic Heterogeneity, Gene Expression Profiling, Epigenesis, Genetic, Kaplan-Meier Estimate, Transcriptome, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.